FLUOROQUINOLONES IN THE TREATMENT OF URINARY TRACT INFECTIONS: WHAT CHANGES THE ANTIBIOTIC RESISTANCE OF UROPATHOGENS?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The clinical and microbiological efficacy of fluoroquinolones at a <20% resistance can be maintained by producing their high concentration (well above the serum ones). Fluoroquinolones (mainly levofloxacin) in high doses have been shown to be effective in the majority of patients with urinary tract infections caused by fluoroquinolone-resistant bacterial strains if their minimal inhibitory concentration is not greater than 32 mg/l.

Full Text

Restricted Access

References

  1. Grabe M., Bjerklund-Johansen T., Botto H. et al. Guidelines on Urological Infections. European Association of Urology 2010: 1-112.
  2. Gupta K., Hooton T., Naber K. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases // Clin. Infect. Dis. - 2011; 52 (5): 103-120.
  3. Eom J., Hwang B., Sohn J. et al. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection // Microb. Drug. Resist. - 2002; 8 (3): 227-234.
  4. Cao X., Cavaco L., Lv Y. et al. Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals // J. Clin. Microbiol. - 2011; 49 (7): 2496-2501.
  5. Khawcharoenporn T., Vasoo S., Ward E. et al. High rates of quinolone resistance among urinary tract infections in the E.D. // Am. J. Emerg. Med - 2012; 30 (1): 68-74.
  6. Johnson L., Sabel A., Burman W. et al. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates // Am.J. Med.- 2008; 121 (10): 876-884.
  7. Gupta K., Hooton T., Naber K. et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases // Clinical Infectious Diseases. -2011; 52 (5): e103-120.
  8. Рафальский, В. В., Страчунский Л. С., Бабкин П. А. и др. Резистентность возбудителей неосложненных инфекций мочевых путей в России // Урология. -2006; 5: 34-37.
  9. Grude N., Potaturkina-Nesterova N., Jenkins A. et al. A comparison of phylogenetic group, virulence factors and antibiotic resistance in Russian and Norwegian isolates of Escherichia coli from urinary tract infection // Clin. Microbiol. Infect. - 2007; 13 (2): 208-211.
  10. Гриднев О. В., Клинико-фармакологические аспекты рациональной антибиотикотерапии инфекций мочевыводящих путей (клинико-экономическое многоцентровое исследование). - М., 2006. - С. 124.
  11. Schito G., Naber K., Botto H. et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections // Int. J. Antimicrob. Agents. - 2009; 34 (5): 407-413.
  12. Hsueh, P., Lau Y., Ko W. et al. Consensus statement on the role of fluoroquinolones in the management of urinary tract infections // J. Microbiol. Immunol. Infect. - 2011; 44 (2): 79-82.
  13. Talan D., Krishnadasan A., Abrahamian F. et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis // Clin. Infect. Dis. 2008; 47 (9): 1150-1158.
  14. Рафальский В. В., Ходневич Л. В. Влияние резистентности возбудителей инфекций мочевыводящих путей на исходы антибактериальной терапии // Урология. - 2008; 4: 3-9.
  15. Clinical and Laboratory Standards Institute, Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M.100-S17. 2007, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA: Clinical and Laboratory Standards Institute. 182.
  16. Stein G., Schooley S., Nicolau D. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli // Int. J. Antimicrob. Agents. - 2008; 32 (4): 320-325.
  17. Deguchi T., Nakane K., Yasuda M. et al. Microbiological outcome of complicated urinary tract infections treated with levofloxacin: a pharmacokinetic/pharmacodynamic analysis // Int. J. Antimicrob. Agents. - 2010; 35 (6): 573-577.
  18. Mille, L., Mehrotra R. and Tang A. Does in vitro fluoroquinolone resistance predict clinical failure in urinary tract infections? // Int. J. Antimicrob. Agents. -2007. 29 (5): 605-607.
  19. Klausner H., Brown P., Peterson J. et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis // Curr. Med. Res. Opin. - 2007. 23 (11): 2637-2645.
  20. Naber K., Llorens L., Kaniga K. et al. Hedrich and R. Redman, Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis // Antimicrob. Agents. Chemother. - 2009. 53 (9): 3782-3792.
  21. Ceran N., Mert D., Kocdogan F. et al. A randomized comparative study of single-dose fosfomycin and 5-ay ciprofloxacin in female patients with uncomplicated lower urinary tract infections // J. Infect. Chemother. - 2010; 16 (6): 424-430.
  22. Рафальский В. В., Малев И. В., Деревицкий А. В. и соавт. Эффективность норфлоксацина при остром цистите в регионе с 10% уровнем резистентности E. coli к фторхинолонам: сравнительное рандомизированное исследование // Урология. - 2009; 3: 18-21.
  23. Yamamoto S., Akiyama K., Yoshimoto T. et al. Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis // J. Infect. Chemother. - 2009; 15 (2): 104-107.
  24. Kang S., Chung D., Park S. et al. Clinical impact of fluoroquinolone resistance in acute pyelonephritis caused by Escherichia coliUrinary tract infections. P.1391 // Clinical Microbiology and Infection. - 2011; 17 (4): 104.
  25. Jeffres M., Shuster J., Barclay S. Treatment of ciprofloxacin nonsusceptible urinary tract infections with ciprofloxacin // Ann. Pharmacother. - 2011; 45 (6): 824-825.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies